ResMed (ASX:RMD): What Does Its December Dividend Mean for CDI Holders?

Sonal Goyal

08 November 2026 11:42 PM AEDT

ResMed (ASX:RMD): What Does Its December Dividend Mean for CDI Holders?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ResMed declared USD 0.66 per common share, equivalent to USD 0.066 per ASX CDI before currency conversion.
The ex-dividend date is 11 November, the Record Date 12 November and payment 17 December 2026.
ASX CDI holders receive an Australian-dollar amount using the record-date Exchange Rate and the 10:1 CDI ratio.

ResMed Inc. (ASX:RMD) develops medical devices, connected care technology and software used in sleep, breathing and residential care. Its latest quarterly Dividend is payable on 17 December 2026. For ASX holders, the entitlement is measured through CHESS Depositary Interests, making the distinction between a common share, a CDI and the final payment currency central to understanding the upcoming distribution.

The dividend is quarterly and the CDI ratio matters

On 29 October 2026, ResMed (ASX:RMD) declared a quarterly dividend of USD 0.66 per common share. Ten ASX CDIs represent one common share, producing an equivalent entitlement of USD 0.066 per CDI before conversion. That CDI amount should not be labelled AUD 0.066.

The ex-dividend date is 11 November 2026, followed by the 12 November record date. Payment is scheduled for 17 December. Holders of ASX CDIs receive the equivalent Australian-dollar amount calculated using the exchange rate on the record date.

For illustration, an eligible holding of 1,000 CDIs corresponds to USD 66 before currency conversion and any applicable deductions. The final Australian-dollar cash amount cannot be fixed in advance of the conversion rate. The smaller CDI amount is a consequence of the security ratio, not a different declared rate for the underlying common share.

ResMed (ASX:RMD) also announced that conversions between its common stock and CDI registers would be deferred from 11 to 12 November inclusive. This temporary register-conversion arrangement is separate from the ordinary cash payment timetable.

September-quarter Earnings provide the operating context

For Q1 FY27, the three months ended 30 September 2026, ResMed (ASX:RMD) reported Revenue of USD 1.415 billion, up 6% YoY. Net Income rose 20% to USD 418 million and diluted earnings per common share increased to USD 2.92 from USD 2.37.

Gross Margin was 61.5%, compared with 61.2% in the corresponding quarter. Revenue growth reflected continued Demand for sleep and breathing health products. The group’s Residential Care Software revenue was affected by the sale of its MatrixCare business, making the change in the Business portfolio relevant to period comparisons.

The dividend declaration therefore accompanies higher quarterly revenue and net income, but those figures are company-wide measures reported in United States dollars. They should not be compared directly with a per-CDI Australian-dollar payment without allowing for both the security ratio and currency conversion.

Cash generation and Capital returns remain separate measures

ResMed (ASX:RMD) reported Q1 FY27 Operating Cash Flow of USD 422 million, compared with USD 457 million a year earlier. Free cash flow was USD 374 million, against USD 414 million. Earnings increased while these cash-flow measures declined, illustrating why both need to be considered.

Cash and cash equivalents were approximately USD 1.0 billion at 30 September 2026. During the quarter the company paid USD 450 million under an accelerated share repurchase agreement, funded in part by proceeds from the MatrixCare divestiture. Repurchases and dividends are distinct uses of capital.

Future dividend decisions remain subject to board approval and the company’s financial position. Product demand, operating expenses, acquisitions or disposals and currency movements can all influence the cash available for Investment and Shareholder distributions.

Key Insights

ResMed (ASX:RMD) has a defined November entitlement timetable and a December payment date. The essential distinction is USD 0.66 per common share versus USD 0.066 per CDI before conversion into Australian dollars. Higher quarterly earnings provide operating context, while cash flows, other capital returns and exchange rates remain relevant to the final income outcome.

FAQs

Q: When is the ex-dividend date?

A:11 November 2026.

Q: When is payment scheduled?

A:17 December 2026, following the 12 November record date.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.